Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Shibei District People's Hospital, Qingdao, China.
Cancer Biother Radiopharm. 2024 Sep;39(7):492-501. doi: 10.1089/cbr.2023.0191. Epub 2024 Jul 1.
This study focuses on acute myeloid leukemia (AML), a condition with a 5-year survival rate below 30% despite various treatment options. Recent strides in targeted therapies have shown promise, leading to better outcomes with minimal toxicity. These advances underscore the importance of discovering new diagnostic and prognostic targets for AML. In this context, the authors investigated the expression of microRNA-106b-5p (miR-106b-5p), Rab10 mRNA, and Rab10 proteins in peripheral blood and bone marrow (BM) samples from both healthy individuals and AML patients at different stages of the disease (initial diagnosis, recurrence, and complete remission). This examination aimed to identify potential biomarkers for AML diagnosis, treatment, and prognosis. From June 2021 to December 2022, they collected 100 BM and peripheral blood samples. The relative expression of miR-106b-5p and Rab10 mRNA in the BM of AML patients was measured using Real-time polymerase chain reaction (qRT-PCR), while the relative expression of Rab10 protein in serum was determined using the ELISA method. The chromosomal karyotype of initially diagnosed patients was analyzed using the R tape. The qRT-PCR results revealed that the expression of miR-106b-5p and Rab10 mRNA were significantly higher in patients at initial diagnosis and recurrence compared with healthy individuals and those in complete remission ( < 0.001). They observed a significant reduction in the expression of miR-106b-5p, Rab10 mRNA, and Rab10 protein in the BM and peripheral blood of patients during complete remission ( < 0.05), as demonstrated by dynamic monitoring of five patients in the initial group. Furthermore, they found a close association between the expression of miR-106b-5p and the number of white blood cells at the initial diagnosis in AML patients ( < 0.05). Spearman correlation analysis revealed a positive correlation among miR-106b-5p, Rab10 mRNA, and Rab10 proteins ( < 0.05). The diagnostic potential of miR-106b-5p and Rab10 proteins was underscored by Receiver Operating Characteristic (ROC) curve analysis, which demonstrated their high accuracy in AML diagnosis (AUC: 0.944 and 0.853, respectively; < 0.0001). Additionally, Kaplan-Meier survival analysis suggested that lower expression of these markers was associated with better prognoses ( < 0.05). In summary, their findings propose miR-106b-5p and Rab10 proteins as promising biomarkers for AML, offering insights for diagnosis, treatment, and prognosis.
这项研究聚焦于急性髓系白血病（AML），尽管有多种治疗选择，但其 5 年生存率仍低于 30%。最近靶向治疗的进展显示出了希望，使毒性最小化的同时取得了更好的结果。这些进展突显了为 AML 发现新的诊断和预后靶点的重要性。在这种情况下，作者研究了外周血和骨髓（BM）样本中微小 RNA-106b-5p（miR-106b-5p）、Rab10mRNA 和 Rab10 蛋白在健康个体和不同疾病阶段（初始诊断、复发和完全缓解）的 AML 患者中的表达。这项检查旨在为 AML 的诊断、治疗和预后寻找潜在的生物标志物。作者于 2021 年 6 月至 2022 年 12 月期间共收集了 100 例 BM 和外周血样本。使用实时聚合酶链反应（qRT-PCR）测量 AML 患者 BM 中 miR-106b-5p 和 Rab10mRNA 的相对表达水平，使用 ELISA 法测定血清中 Rab10 蛋白的相对表达水平。对初始诊断患者的染色体核型进行了 R 带分析。qRT-PCR 结果显示，与健康个体和完全缓解患者相比，初始诊断和复发患者的 miR-106b-5p 和 Rab10mRNA 表达显著升高（<0.001）。他们观察到，在完全缓解期间，患者的 BM 和外周血中的 miR-106b-5p、Rab10mRNA 和 Rab10 蛋白的表达显著降低（<0.05），对初始组中的五名患者进行了动态监测。此外，他们发现 AML 患者初始诊断时白细胞数量的表达与 miR-106b-5p 密切相关（<0.05）。Spearman 相关性分析显示 miR-106b-5p、Rab10mRNA 和 Rab10 蛋白之间呈正相关（<0.05）。接受者操作特征（ROC）曲线分析强调了 miR-106b-5p 和 Rab10 蛋白的诊断潜力，表明它们在 AML 诊断中具有很高的准确性（AUC：0.944 和 0.853，分别；<0.0001）。此外，Kaplan-Meier 生存分析表明，这些标志物的低表达与更好的预后相关（<0.05）。综上所述，研究结果表明 miR-106b-5p 和 Rab10 蛋白是 AML 的有前途的生物标志物，为诊断、治疗和预后提供了新的见解。
